Plain-English translation of NCT06607796 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new treatment called toluenesulfonamide (PTS) that is injected directly into tumors in people with stage IV non-small cell lung cancer. The researchers want to see if this medication, used alone or combined with standard chemotherapy and immunotherapy, can help shrink or control the cancer. The goal is to find out whether this approach is safe and effective.
Many people with advanced lung cancer need better treatment options, especially when their cancers don't have certain genetic mutations that make them easier to target with existing drugs. This medication offers a new approach by delivering treatment directly to the tumor, which may help reduce side effects and improve how well it works.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will either receive direct injections of the medication into your lung tumors, or you will be closely monitored without the injections at first (though you may receive them later if your cancer progresses). You'll have regular appointments for imaging scans, blood tests, and check-ups to track how your cancer responds and monitor for any side effects. The study involves 180 participants total and will track your progress over time.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China